Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transitions and appointments designed to align the company’s leadership structure... Read More

FOSTER CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 966,000 shares of its common stock, consisting of stock options to purchase an aggregate of 644,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 322,000 shares of common... Read More

FOSTER CITY, Calif. / Aug 27, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that management is scheduled to participate in a fireside chat on September 4, 2025 at the 2025 Wells Fargo Healthcare Conference in Boston, MA. A live webcast of the presentation will be available at ir.geron.com and will be posted on the Investors and Media section of Geron’s... Read More

FOSTER CITY, Calif. / Aug 18, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 522,000 shares of its common stock, consisting of stock options to purchase an aggregate of 348,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 174,000 shares of common stock,... Read More

FOSTER CITY, Calif. / Aug 08, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to purchase 11,000,000 shares of common stock to Harout Semerjian, Geron’s new President and Chief Executive Officer, as an inducement material to his acceptance of employment with Geron. The stock options were... Read More

Seasoned Commercial Hematology and Oncology Leader Harout Semerjian Appointed as President and CEO Achieved $49.0 million in RYTELO® net product revenue in Q2 2025 Phase 3 IMpactMF clinical trial in relapsed/refractory myelofibrosis is over 95% enrolled and expected to be fully enrolled by year-end Company to host conference call and webcast today, August 6, at 8:00 a.m. ET FOSTER CITY, Calif. / Aug 06, 2025 / Business Wire... Read More

Industry veteran brings 30+ years of commercial hematology and oncology experience to help accelerate Geron’s next phase of growth FOSTER CITY, Calif. / Aug 06, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Harout Semerjian as President and Chief Executive Officer (CEO) and... Read More

FOSTER CITY, Calif. / Jul 28, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today announced that it will release its second quarter financial results and business highlights before the market opens on Wednesday, August 6, 2025 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a conference call to discuss... Read More

FOSTER CITY, Calif. / Jul 18, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 342,000 shares of its common stock, consisting of stock options to purchase an aggregate of 228,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 114,000 shares of common stock,... Read More

FOSTER CITY, Calif. / Jun 18, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,116,000 shares of its common stock, consisting of stock options to purchase an aggregate of 744,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 372,000 shares of common... Read More

New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status, baseline serum erythropoietin (sEPO) level, or prior therapy use Health-related quality-of-life (QOL) data and results on time without transfusion reliance (TWiTR) provide deeper insights into patient-centric outcomes with RYTELO in LR-MDS... Read More

FOSTER CITY, Calif. / May 19, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000 shares of its common stock, consisting of stock options to purchase an aggregate of 274,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 137,000 shares of common stock,... Read More

Reported $39.4 million in RYTELO® (imetelstat) net product revenue in Q1 2025; revenue impacted by inventory dynamics, with Q1 demand relatively flat Granted marketing authorization of RYTELO by the European Commission (EC); planning for commercial launch in select EU countries 2026 Reached approximately 85% enrollment in the Phase 3 IMpactMF clinical trial for treatment of relapsed/refractory myelofibrosis; interim analysis... Read More

FOSTER CITY, Calif. / Apr 18, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,551,000 shares of its common stock, consisting of stock options to purchase an aggregate of 1,034,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 517,000 shares of common... Read More

FOSTER CITY, Calif. / Mar 31, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its first quarter financial results and business highlights before the market opens on Wednesday, May 7, 2025 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a conference call to discuss the... Read More

FOSTER CITY, Calif. / Mar 19, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 225,000 shares of its common stock, consisting of stock options to purchase an aggregate of 150,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 75,000 shares of common stock, to... Read More

Approval across ESA ineligible and ESA relapsed/refractory non-del 5q patients with transfusion-dependent anemia due to LR-MDS, regardless of ring sideroblast (RS) status RYTELO is the first and only telomerase inhibitor approved in the U.S. and Europe FOSTER CITY, Calif. / Mar 11, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the... Read More

FOSTER CITY, Calif. / Mar 11, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John “Chip” A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience... Read More

Achieved $47.5 million in RYTELO™ (imetelstat) net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024, following FDA approval Expect to reach profitability without additional financing if current internal sales and operating expenses expectations are met FOSTER CITY, Calif. / Feb 26, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company... Read More

FOSTER CITY, Calif. / Feb 21, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in fireside chats at the following investor conferences: TD Cowen 45th Annual Health Care Conference Monday, March 3 rd at 3:10pm ET (Boston, MA) Leerink Global Healthcare Conference Monday, March 10 th 3:00pm ET... Read More

FOSTER CITY, Calif. / Feb 19, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 180,000 shares of its common stock, consisting of stock options to purchase an aggregate of 120,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 60,000 shares of common stock, to... Read More

FOSTER CITY, Calif. / Feb 03, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2024 financial results and business highlights before the market opens on Wednesday, February 26, 2025 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a... Read More

FOSTER CITY, Calif. / Jan 21, 2025 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 312,000 shares of its common stock, consisting of stock options to purchase an aggregate of 208,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 104,000 shares of common stock,... Read More

FOSTER CITY, Calif. / Dec 19, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 72,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on December 18, 2024, at an... Read More

FOSTER CITY, Calif. / Dec 13, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treatment of adult patients... Read More

Analyses pooling data from IMerge Phase 2, Phase 3 and the QTc substudy suggest patients who were ESA ineligible or who had prior treatment with luspatercept or lenalidomide experienced clinical benefit from imetelstat similar to prior results from the IMerge pivotal trial Data from the QTc substudy reinforce imetelstat as a second-line treatment option for LR-MDS patients with transfusion-dependent anemia regardless of... Read More

In the dose escalation Part 1 of the study, no dose-limiting toxicities were observed and the PK profiles were similar to those reported for previous monotherapy studies of imetelstat and ruxolitinib Based on the safety profile, imetelstat 9.4 mg/kg dosed every four weeks with ruxolitinib was the selected dose for the dose expansion Part 2 of the study, which is currently enrolling patients Geron is also evaluating the... Read More

FOSTER CITY, Calif. / Nov 27, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in a fireside chat at the 7 th Annual Evercore ISI HealthCONx Conference, in Coral Gables, Florida on Wednesday, December 4, 2024, at 8:20 a.m. ET. A webcast of the fireside chat will be available through the... Read More

FOSTER CITY, Calif. / Nov 21, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 1,017,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on November 20, 2024, at an... Read More

FOSTER CITY, Calif. / Nov 11, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization comprised of... Read More

FOSTER CITY, Calif. / Nov 11, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to participate in a fireside chat at the Stifel 2024 Healthcare Conference, in New York City, on Monday, November 18 th , 2024, at 1:50pm ET. A webcast of the fireside chat will be available through the Investors and Media section of... Read More

Geron received $250 million in gross proceeds at closing, with access to an additional $125 million in debt Strengthens balance sheet to support the commercial launch of RYTELO™ in the U.S. and potential launch in the EU, the ongoing Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis, and other uses FOSTER CITY, Calif. / Nov 07, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage... Read More

Achieved $28.2 million in RYTELO™ (imetelstat) net product revenue in first full quarter of sales Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt FOSTER CITY, Calif. / Nov 07, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change... Read More

New analyses from the IMerge clinical trial suggest that imetelstat demonstrates clinical activity in patients with lower-risk MDS with transfusion-dependent anemia regardless of prior therapy Early safety results from the dose escalation phase of the Phase 1 IMproveMF study suggest potential for the tolerability of combination therapy with imetelstat and ruxolitinib in a frontline myelofibrosis patient population FOSTER... Read More

FOSTER CITY, Calif. / Oct 17, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 680,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on October 16, 2024, at an... Read More

FOSTER CITY, Calif. / Oct 15, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and business highlights before the market opens on Thursday, November 7, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a conference call to... Read More

FOSTER CITY, Calif. / Sep 19, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 500,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on September 18, 2024, at an... Read More

FOSTER CITY, Calif. / Sep 09, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron’s global commercial strategy and operations, lead the... Read More

FOSTER CITY, Calif. / Aug 22, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 261,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on August 21, 2024, at an... Read More

U.S. commercial launch of RYTELO™ (imetelstat) began in June 2024 for patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia who are relapsed/refractory to or ineligible for erythropoiesis-stimulating agents (ESAs), regardless of ring sideroblast (RS) status NCCN Guidelines® updated to include the use of RYTELO in both RS+ and RS- patients for second-line treatment of symptomatic anemia... Read More

RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) FOSTER CITY, Calif. / Jul 26, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that... Read More

FOSTER CITY, Calif. / Jul 23, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to pursue other interests. A search for a new Chief Commercial Officer is already... Read More

FOSTER CITY, Calif. / Jul 18, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a conference call to... Read More

FOSTER CITY, Calif. / Jun 20, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 222,660 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on June 19, 2024, at an exercise... Read More

Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast (RS) status Durable and sustained red blood cell transfusion independence, increases in hemoglobin levels and reduction in transfusion burden observed across key LR-MDS subgroups in the IMerge Phase 3 clinical trial; the most common Grade 3/4 adverse reactions were thrombocytopenia... Read More

FOSTER CITY, Calif. / May 16, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 2,910,780 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on May 15, 2024, at an... Read More

June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS FOSTER CITY, Calif. / May 02, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business... Read More

FOSTER CITY, Calif. / Apr 25, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a conference call to discuss... Read More

FOSTER CITY, Calif. / Apr 18, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on April 17, 2024, at an... Read More

FOSTER CITY, Calif. / Apr 03, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences: 23 rd Annual Needham Virtual Healthcare Conference Wednesday, April 10 th at 10:15 a.m. ET (Fireside Chat) Stifel’s 2024 Virtual... Read More

FOSTER CITY, Calif. / Mar 19, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock. The pre-funded warrants are being sold at a price of $2.999 per pre-funded... Read More

FDA Oncologic Drugs Advisory Committee voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat based on results from the IMerge Phase 3 clinical trial There are significant unmet needs across key TD LR-MDS patient populations, including difficult-to-treat subgroups that are underserved by currently available treatment options June 16, 2024 PDUFA target action date for imetelstat NDA for the treatment of TD... Read More

June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS FOSTER CITY, Calif. / Feb 28, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial... Read More

FOSTER CITY, Calif. / Feb 22, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 397,010 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on February 21, 2024, at an... Read More

FOSTER CITY, Calif. / Feb 14, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2023 financial results and business highlights before the market opens on Wednesday, February 28, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a... Read More

FOSTER CITY, Calif. / Jan 18, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 895,930 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on January 17, 2024, at an... Read More

FOSTER CITY, Calif. / Jan 12, 2024 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat at the B. Riley Securities Virtual Oncology Conference on Thursday, January 18 th , 2024, at 10:30am ET. A webcast of the presentation will be available... Read More

FOSTER CITY, Calif. / Dec 21, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 417,490 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on December 20, 2023 at an... Read More

Imetelstat is currently under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS FOSTER CITY, Calif. / Dec 11, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from its IMerge Phase 3 clinical trial evaluating first-in-class investigational telomerase... Read More

IMpactMF is the first and only Phase 3 clinical trial to evaluate overall survival as the primary endpoint in R/R MF An interim analysis is expected in the first half of 2025, with a final analysis expected in the first half of 2026 FOSTER CITY, Calif. / Dec 06, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in... Read More

Imetelstat is currently under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS FOSTER CITY, Calif. / Dec 04, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients... Read More

FOSTER CITY, Calif. / Nov 28, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors. Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a history of expertise in financial and corporate strategy, as well as business development,... Read More

FOSTER CITY, Calif. / Nov 16, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 438,950 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on November 15, 2023 at an... Read More

FOSTER CITY, Calif. / Nov 07, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences: Stifel 2023 Healthcare Conference Tuesday, November 14 th at 9:10 a.m. ET (Fireside Chat) Piper Sandler 35 th Annual Healthcare Conference... Read More

Subgroup analyses showed consistently higher transfusion independence (TI) response rates than placebo across different risk groups regardless of International Prognostic Scoring System (IPSS), revised IPSS (IPSS-R) or IPSS molecular (IPSS-M) Robust TI rates with imetelstat treatment compared with placebo in patients with poor prognosis mutational profiles For the nearly 20% of imetelstat-treated patients who achieved... Read More

Imetelstat is currently under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS Planning is ongoing for a potential commercial launch in the U.S. in mid-2024 FOSTER CITY, Calif. / Nov 02, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor,... Read More

FOSTER CITY, Calif. / Oct 26, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its third quarter 2023 financial results and business highlights before the market opens on Thursday, November 2, 2023 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a conference call to... Read More

FOSTER CITY, Calif. / Oct 19, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 401,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on October 18, 2023 at an... Read More

FOSTER CITY, Calif. / Sep 29, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for imetelstat, a first-in-class investigational telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes... Read More

FOSTER CITY, Calif. / Sep 11, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023. Ms. Robertson's appointment follows the retirement of Olivia Bloom, Geron's incumbent CFO, also effective September 25, 2023. Ms.... Read More

FOSTER CITY, Calif. / Sep 07, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced poster presentations of data from IMerge, the Company’s Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat vs. placebo in patients with lower risk myelodysplastic syndromes (MDS) at the eleventh annual Society of Hematologic... Read More

FOSTER CITY, Calif. / Sep 05, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Baird 2023 Global Healthcare Conference in New York City, NY, on Tuesday, September 12, 2023, at 4:55 p.m. ET. A webcast of the... Read More

FOSTER CITY, Calif. / Aug 22, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has assigned a standard review and a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 for Geron’s New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in... Read More

FOSTER CITY, Calif. / Aug 21, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has accepted the filing of Geron’s New Drug Application (NDA) for imetelstat, its first-in-class telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic... Read More

FOSTER CITY, Calif. / Aug 17, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 189,850 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on August 16, 2023 at an exercise price of $2.70 per share, which is equal to... Read More

Submitted U.S. New Drug Application in lower risk MDS in June 2023 Additional data and analyses from IMerge Phase 3 presented at medical meetings further strengthen value proposition and differentiation of imetelstat Potential U.S. commercial launch in lower risk MDS expected in first half of 2024 FOSTER CITY, Calif. / Aug 03, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical... Read More

FOSTER CITY, Calif. / Jul 27, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its second quarter 2023 financial results on Thursday, August 3, 2023 at 4:00 p.m. Eastern Time via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a conference call to discuss the financial... Read More

FOSTER CITY, Calif. / Jul 20, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 130,050 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on July 19, 2023 at an exercise price of $3.24 per share, which is equal to the... Read More

FOSTER CITY, Calif. / Jun 29, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that an Expanded Access Protocol (EAP) is available for imetelstat, the Company’s first-in-class telomerase inhibitor. As allowed under the U.S. Food and Drug Administration (FDA) policies, companies may offer an EAP, which permits an investigational medicinal product... Read More

FOSTER CITY, Calif. / Jun 22, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 72,770 shares of Geron common stock as inducements to a newly hired employee in connection with commencement of employment with the Company. The stock options were granted on June 21, 2023 at an exercise price of $3.22 per share, which is equal to the... Read More

FOSTER CITY, Calif. / Jun 20, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the submission to the United States Food and Drug Administration (FDA) of a New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have failed to... Read More

First clinical trial to explore the potential of imetelstat in relapsed/refractory acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (MDS) Data from animal pre-clinical models indicated imetelstat prevented expansion of human AML leukemic stem cells and prolonged survival of mice FOSTER CITY, Calif. / Jun 13, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical... Read More

New analyses from IMerge Phase 3 reported higher 24-week transfusion independence (TI) responses for imetelstat-treated patients vs. placebo across key myelodysplastic syndromes (MDS) subgroups and across spectrum of MDS mutations New data and analyses indicated greater variant allele frequency (VAF) reductions for imetelstat-treated patients vs. placebo across multiple genes commonly mutated in MDS; these reductions also... Read More

FOSTER CITY, Calif. / Jun 07, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Goldman Sachs 44 th Annual Global Healthcare Conference in Dana Point, CA, on Thursday, June 15, 2023 at 8:40 a.m. PT. A webcast of the... Read More

FOSTER CITY, Calif. / Jun 06, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, will host a virtual investor event on Wednesday, June 14, 2023 at 8:00 a.m. Eastern Time. Topics to be covered at the event include: Summary of new IMerge Phase 3 data in lower risk myelodysplastic syndromes (MDS) featured in 2023 medical meetings. This includes presentation of data at the... Read More

Primary endpoint of 8-week transfusion independence (TI) significantly higher with imetelstat vs. placebo (P<0.001), with median TI duration approaching one year for imetelstat 8-week TI responders Statistically significant and clinically meaningful efficacy results achieved across key MDS subgroups: ring sideroblast (RS) status, baseline transfusion burden and IPSS risk category Safety results consistent with prior... Read More

Data support NDA submission which is on track for June 2023 to support potential U.S. commercial launch in first half of 2024 FOSTER CITY, Calif. / May 25, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced acceptance of its IMerge Phase 3 abstract as an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.... Read More

FOSTER CITY, Calif. / May 18, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 128,840 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on May 17, 2023 at an exercise price of $3.02 per share, which is equal to the... Read More

Longer follow-up data for 1-year transfusion independence (TI) in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy Strong correlation of reduction in MDS-associated mutations with clinical benefits, including TI duration, provides compelling evidence for the potential of disease modification Based on PRO data, imetelstat-treated patients were more likely to... Read More

Planned submission of U.S. New Drug Application on track for June 2023 Additional data and analyses from IMerge Phase 3 expected to be presented at upcoming medical meetings further strengthen differentiating qualities of imetelstat Preparations for potential commercial launch in the U.S. ongoing FOSTER CITY, Calif. / May 11, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical... Read More

FOSTER CITY, Calif. / May 04, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023 at 8:00 a.m. Eastern Time via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a conference call to discuss the financial... Read More

FOSTER CITY, Calif. / Apr 26, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the pivotal IMerge Phase 3 clinical trial evaluating the Company’s first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS), was accepted for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual... Read More

FOSTER CITY, Calif. / Apr 20, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 1,684,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on April 19, 2023 at an exercise price of $2.49 per share, which is equal to... Read More

FOSTER CITY, Calif. / Apr 12, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in fireside chats at following investor conferences: 22 nd Annual Needham Virtual Healthcare Conference Thursday, April 20 at 10:15 a.m. ET Stifel 2023 Virtual Targeted... Read More

FOSTER CITY, Calif. / Mar 16, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 490,630 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on March 15, 2023 at an exercise price of $2.62 per share, which is equal to... Read More

FOSTER CITY, Calif. / Mar 16, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2022. “With positive top-line results having been reported for IMerge... Read More

FOSTER CITY, Calif. / Mar 09, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2022 financial results after the market closes on Thursday, March 16, 2023 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a conference call to discuss the... Read More

FOSTER CITY, Calif. / Feb 16, 2023 / Business Wire / Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 640,550 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on February 15, 2023 at an exercise price of $2.69 per share, which is equal to... Read More

Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 75,730 shares of Geron common stock as inducements to a newly hired employee in connection with commencement of employment with the Company. The stock options were granted on January 18, 2023 at an exercise price of $3.12 per share, which is equal to the closing price of Geron common stock on the date... Read More

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the B. Riley Securities 3 rd Annual Virtual Oncology Conference on January 18 at 1 p.m. ET. A live webcast of the presentation will be available through the Investor Relations section of Geron’s... Read More

Leadership in place for core commercial functions, including in Market Access, Trade & Channel Relations, Commercial Operations, Analytics, Marketing, Sales and Medical Affairs Company continues stage-gated commercial readiness efforts for an anticipated commercial launch of imetelstat in lower risk MDS in the first half of 2024 in the U.S. and by the end of 2024 in the EU, assuming regulatory approvals are granted Geron... Read More

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its upsized underwritten public offering of common stock and pre-funded warrants, plus the full exercise of the underwriters’ option to purchase additional shares of common stock for total gross proceeds of $227.8 million. All of the securities in the offering were sold by Geron. The estimated net proceeds to... Read More

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an upsized underwritten public offering consisting of 55,876,297 shares of its common stock at a public offering price of $2.45 per share and pre-funded warrants to purchase 25,000,000 shares of its common stock. The pre-funded warrants are being sold at a public offering price of $2.449 per pre-funded warrant.... Read More

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell $175 million of shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. Geron intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered... Read More

Trial met primary 8-week transfusion independence (TI) endpoint and key secondary 24-week TI endpoint with highly statistically significant and clinically meaningful improvements Median TI duration approaching one year for imetelstat 8-week TI responders and 1.5 years for imetelstat 24-week TI responders Statistically significant and clinically meaningful efficacy results achieved across key MDS subtypes, including ring... Read More

Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to discuss top-line results from the IMerge Phase 3 clinical trial of imetelstat, the Company’s first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS) on January 4, 2023, at 8:00 a.m. ET. A live webcast of the conference call and related presentation will be available on the Company’s website at... Read More

Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 867,130 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on December 21, 2022 at an exercise price of $2.08 per share, which is equal to the closing price of Geron common stock on the date... Read More

≥1 year durable transfusion independence (1-year TI) achieved in 29% of IMerge Phase 2 patients, with a median TI duration of 1.8 years In patients previously treated with luspatercept, 33% achieved 1-year TI Strong evidence of disease modification in patients with 1-year TI as indicated by ≥3g/dL increases in hemoglobin, as well as reductions in SF3B1 variant allele frequency (VAF) that were correlated with longer TI... Read More